Pet Pharm Biotech Co., Ltd. (TPEX:7762)

Market Cap	3.94B
Revenue (ttm)	159.02M
Net Income (ttm)	19.25M
Shares Out	51.21M
EPS (ttm)	0.41
PE Ratio	187.86
Forward PE	n/a
Dividend	0.09 (0.11%)
Ex-Dividend Date	Aug 25, 2025

Volume	42,965
Average Volume	130,498
Open	79.30
Previous Close	78.60
Day's Range	77.10 - 79.30
52-Week Range	38.78 - 91.20
Beta	n/a
RSI	41.90
Earnings Date	Nov 13, 2025

About Pet Pharm Biotech

Pet Pharm Biotech Co., Ltd. manufactures and sells pharmaceutical products. The company also engages in the research, development, and production of nuclear medicine drugs. Its products include FDG fluodeoxyglucose, naolixi, and sodium fluoride injections; and radioactive sodium iodide capsules. The company was founded in 2011 and is based in New Taipei City, Taiwan.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7762

Financial Performance

In 2024, Pet Pharm Biotech's revenue was 130.70 million, an increase of 10.89% compared to the previous year's 117.87 million. Earnings were 14.51 million, an increase of 58.54%.